Genmab A/S (GMAB) fair value analysis
Nasdaq · Updated 2026-10-19
GMAB price how computed
Forward Fair Value verdict
OvervaluedGMAB is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $37.00
- Sector
- Healthcare
- 12-month range
- $23.85–$38.48
- Market cap
- $22.8B
- From 52-week high
- -3.8%
- Shares outstanding
- 615M
- Rank in Healthcare by discount to fair value
- #76 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Genmab A/S is a Danish biotechnology company that develops and commercializes monoclonal antibody-based therapeutic drugs for the treatment of cancer, autoimmune, and infectious diseases. The company operates globally with research, development, and commercial operations across Europe, North America, and other international markets.
GMAB currently ranks #76 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 4 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $22.8B
- P/E (trailing)
- 24x
- Revenue (TTM)
- $4.13B
- Net margin
- 19.1%
- EPS (TTM)
- $1.53
- Gross margin
- 92.7%
- Debt / equity
- 0.89
- Revenue growth (3-yr avg)
- -25.2%
- Shares outstanding
- 615M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 58 · neutral
- 50-day average
- $34.31
- 200-day average
- $29.86
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-05 (pre-market)
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+45.9%)
2026-03 ▼ miss (-31.6%)
2025-12 ▼ miss (-43.2%)
2025-09 ▲ beat (+44.4%)
2025-06 ▲ beat (+38.5%)
2025-03 ▲ beat (+34.8%)
2024-12 ▲ beat (+200.0%)
2024-09 ▼ miss (-12.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 1 hold · 0 sell (11 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $44.4
- Target vs last price
- +20.0%
What our data shows for GMAB
- Our model validated 17 trailing price-to-earnings windows for GMAB, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $23.85–$38.48.
- The 14-day relative strength index sits at a neutral 58.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for GMAB
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent GMAB news
TickrTrends' derived news-sentiment signal for GMAB is currently mixed, computed from recent coverage.
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026 (manilatimes.net, 2026-10-13)
TickrTrends take: Genmab's DARZALEX net sales announcement for Q3 2026 provides concrete revenue data that investors should evaluate against TickrTrends' current overvalued assessment of the company. Since DARZALEX represents a significant portion of Genmab's revenue as a key multiple myeloma treatment, the magnitude of these sales figures will be essential for determining whether the current valuation appropriately reflects the drug's market performance and growth trajectory. Healthcare investors monitoring GMAB should compare the reported sales results to prior quarters and analyst expectations to assess whether the company's valuation premium is justified by its commercial execution. - Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members (manilatimes.net, 2026-10-07)
TickrTrends take: Genmab A/S held an extraordinary general meeting where restricted stock units were granted to board members, a corporate governance action that ties leadership compensation more directly to shareholder value creation. Given TickrTrends' assessment that GMAB is fairly valued, investors should monitor whether such equity-based incentive structures demonstrate management confidence in the company's pipeline and market position within the competitive Healthcare sector. The alignment of board compensation with long-term equity performance may be particularly relevant for shareholders evaluating whether the current valuation properly reflects the company's growth prospects and execution risks. - GMAB Maintained by Guggenheim -- Price Target Raised to $54.00 (gurufocus.com, 2026-10-05)
TickrTrends take: Guggenheim's maintenance of coverage alongside a price target raise to $54 suggests analyst confidence in GMAB's fundamentals within the Healthcare sector, aligning with TickrTrends' fairly valued assessment. Investors focused on valuation metrics should monitor whether GMAB's operational performance and financial trajectory can support movement toward or away from this elevated price target, as significant gaps between current pricing and analyst targets often signal either market inefficiency or changing risk factors.
What people are saying
Follow the GMAB conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — GMAB is a healthcare sector stock that TickrTrends' derived indicators moved this week as follows: the quality grade improved from D to C, the sector discount rank declined from 84 to 92, and the valuation verdict shifted from Fairly valued to Overvalued. The stock currently carries an Overvalued designation according to TickrTrends' assessment.
- 2026-10-05 — GMAB's sector discount rank declined this week, moving from #79 to #84 among Healthcare sector stocks. The company maintains a Fairly valued assessment based on current valuation metrics.
- 2026-09-28 — GMAB's sector discount ranking declined this week, moving from number 71 to number 79 among Healthcare sector stocks. This shift indicates the stock has become relatively less discounted compared to its sector peers. The stock maintains a Fairly valued assessment according to TickrTrends' derived indicators.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is GMAB stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), GMAB is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is GMAB's TickrTrends verdict?
GMAB's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does GMAB compare to other Healthcare stocks?
GMAB ranks #76 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is GMAB overbought or oversold?
GMAB's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does GMAB report earnings next?
GMAB's next earnings report is scheduled for 2026-11-05 (pre-market), per the published earnings calendar.
Does GMAB usually beat earnings estimates?
Over its last 8 reported quarters GMAB beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about GMAB?
Of 11 analysts covering GMAB, 10 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $44.4 (+20.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
GMAB vs ABBV · GMAB vs ACAD · GMAB vs AGIO · GMAB vs AMGN · GMAB vs BIIB